Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and Management

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Manuel Hidalgo, Lillian L. Siu, John Nemunaitis et al. · Journal of Clinical Oncology · 2001 · 997 citations

Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial

Roy S. Herbst, Anne‐Marie Maddox, Mace L. Rothenberg et al. · Journal of Clinical Oncology · 2002 · 577 citations

Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition

J. Albanell · Journal of Clinical Oncology · 2002 · 492 citations

Phase I Study of Anti–Epidermal Growth Factor Receptor Antibody Cetuximab in Combination With Radiation Therapy in Patients With Advanced Head and Neck Cancer

Francisco Robert, Mark P. Ezekiel, Sharon A. Spencer et al. · Journal of Clinical Oncology · 2001 · 473 citations

Monoclonal antibodies to target epidermal growth factor receptor–positive tumors

Roy S. Herbst, Dong M. Shin · Cancer · 2002 · 449 citations · Full text